G. Kolvenbag

发表

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

T. Tammela, J. Montie, M. Wirth, 2002, The Journal of urology.

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.

P. Schellhammer, G. Haas, E. Klein, 1997, The Journal of urology.

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues

P. Schellhammer, N. Vogelzang, M. Soloway, 1999, The Prostate.

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1995, Urology.

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone–Releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression

P. Schellhammer, N. Vogelzang, Yusong Chen, 1996, Cancer.

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

T. Tammela, J. Montie, M. Wirth, 2002, The Journal of urology.

Comparison of goserelin and leuprolide in combined androgen blockade therapy.

P. Schellhammer, E. Klein, N. Vogelzang, 1998, Urology.

Androgen antagonists: Potential role in prostate cancer prevention.

D. Trump, J. Waldstreicher, B. Neubauer, 2001, Urology.

Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?

P. Schellhammer, M. Sarosdy, K. Carroll, 2000, Urology.

Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group.

F. Debruyne, G. Kolvenbag, G. A. Dijkman, 1996, Urology.

Bicalutamide and Flutamide, Each in Combination with Luteinizing Hormone-Releasing Hormone Analogs, in Advanced Prostate Cancer: Exploratory Analysis of Impact of Extent of Disease by Bone Scan on Outcome

P. Schellhammer, N. Vogelzang, M. Soloway, 2000 .

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1997, Urology.

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1996, European urology.

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1996, Urology.

Serum PSA decline after Casodex withdrawal.

P. Schellhammer, G. Kolvenbag, 1994, Urology.

Erattum: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial (Urology (September 1997) 50 (330-336))

P. Schellhammer, N. Vogelzang, M. Soloway, 1998 .

Estimated potency of casodex: A problematic design [1] (multiple letters)

P. Schellhammer, J. Simard, N. Vogelzang, 1997 .

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.

G. Bubley, S. Balk, M. Taplin, 1998, The Journal of urology.

Bicalutamide (Casodex®) in the treatment of prostate cancer: History of clinical development

G. Blackledge, G. Kolvenbag, G. Kolvenbag, 1998, The Prostate.

Prospective study relating genotype profiles with race performance in racing pigeons

E. D. de Kloet, G. Kolvenbag, Arne H de Kloet, 2022, Journal of Applied Genetics.

The Impact of Gender in Young Bird Pigeon Racing

G. Kolvenbag, 2022, Corpus Journal of Dairy and Veterinary Science (CJDVS).

Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.

D. Newling, P. Iversen, P Iversen, 2001, Urology.

Bicalutamide dosages used in the treatment of prostate cancer

G. Kolvenbag, G. Kolvenbag, A. Nash, 1999, The Prostate.

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer.

A. Howell, J. Forbes, R. Blamey, 1995, European journal of cancer.